Antileishmanial activity of a formulation of 2-n-propylquinoline by oral route in mice model

Parasite

Volumn 18, Issue 4, 2011, Pages 333-336

  Campos Vieira, N ^a   Vacus, J ^b   Fournet, A ^c   Baudouin, R ^b   Bories, C ^a   Seon Meniel B ^c   Figadere B ^c   Loiseau, P M ^a  

^a UNIVERSITÉ PARIS SUD   (France)

^b Société Drugabilis   (France)

^c UNIVERSITÉ DE LIMOGES   (France)

Author keywords

Antileishmanial; Drug formulation; Leishmaniosis; Quinoline

Indexed keywords

LEISHMANIA DONOVANI; MUS;

EID: 84855275109     PISSN: 1252607X     EISSN: 17761042     Source Type: Journal    
DOI: 10.1051/parasite/2011184333     Document Type: Article

References (10)

1. CAMPOS-VIEIRA N., HERRENKNECHT C., VACUS J., FOURNET A., BORIES C., FIGADÈRE B., SALMEN ESPINDOLA L. & LOISEAU P.M. Selection of the most promising 2-substituted quinoline as antileishmanial candidate for clinical trials. Biomedicine and Pharmacotherapy, 2008, 62, 684-689.
2. FAKHFAKH M.A., FOURNET A., PRINA E., MOUSCADET J.F., FRANCK X., HOCQUEMILLER R. & FIGADERE B. Synthesis and biological evaluation of substituted quinolines: potential treatment of protozoal and retroviral coinfections. Bioorganic and Medicinal Chemistry, 2003, 11, 5013-5023. (Pubitemid 37352989)
3. FOURNET A., BARRIOS A.A., MUÑOZ V., HOCQUEMILLER R., CAVÉ A. & BRUNETON J. 2-substituted quinoline alkaloids as potential antileishmanial drugs. Antimicrobial Agents and Chemotherapy, 1993, 37, 859-863. (Pubitemid 23096891)
4. FOURNET A., FERREIRA M.E., ROJAS DE ARIAS A., TORRES DE ORTIZ S., FUENTES S., NAKAYAMA H., SCHININI A. & HOCQUEMILLER R. In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensis. Antimicrobial Agents and Chemotherapy, 1996, 40, 2447-2451. (Pubitemid 26367623)
5. IGLARZ M., BAUNE B., GANTIER J.C., HOCQUEMILLER R. & FARINOTTI R. Determination of 2-n-propylquinoline in mouse plasma and liver by high-performance liquid chromatography. Journal of Chromatography B Biomedical Applications, 1998, 714, 335-340. (Pubitemid 28386856)
6. MBONGO N., LOISEAU P.M., BILLION M.A. & ROBERT-GERO M. Mechanism of Amphotericin B resistance in Leishmania donovani promastigotes. Antimicrobial Agents and Chemotherapy, 1998, 42, 352-357. (Pubitemid 28114444)
7. NAKAYAMA H., LOISEAU P.M., BORIES C., TORRES DE ORTOZ S., SHININI A., SERNA E., ROJAS DE ARIAS A., FAKHFAKH M.A., FRANCK X., FIGADÈRE B., HOCQUEMILLER R. & FOURNET A. Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and viceral leishmaniasis. Antimicrobial Agents and Chemotherapy, 2005, 49, 4950-4956. (Pubitemid 41778905)
8. NAKAYAMA H., DESRIVOT J., BORIES C., FRANCK X., FIGADÈRE B., HOCQUEMILLER R., FOURNET A. & LOISEAU P.M. In vitro and in vivo antileishmanial efficacy of a new nitrilquinoline against Leishmania donovani. Biomedicine and Pharmacotherapy, 2007, 61, 186-188. (Pubitemid 46578284)
9. SEIFERT K., MATU S., PÉREZ-VICTORIA J., CASTANYS S., GAMARRO F. & CROFT S.L. Characterization of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). International Journal of Antimicrobial Agents, 2003, 22, 380-387. (Pubitemid 37163727)
10. WHO - WORLD HEALTH ORGANIZATION. Control of Leishmaniasis, Sixtieth World Health Assembly, Provisional agenda item 12.3, A60/10, 22 march 2007.